<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03106766</url>
  </required_header>
  <id_info>
    <org_study_id>CSP-004</org_study_id>
    <nct_id>NCT03106766</nct_id>
  </id_info>
  <brief_title>Six Months Evaluation of Next Science Acne Creams on Facial Acne in Adult Females.</brief_title>
  <official_title>A Single-center, Double-blind, Controlled Study to Evaluate the Effect of Next Science™ Acne Cream on Mild to Moderate Facial Acne in Adult Females Over 6 Months.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Next Science TM</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Skin Laser &amp; Surgery Specialists</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Next Science TM</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess facial acne vulgaris clinical and psychological outcomes by measuring differences
      in lesions counts, investigator global assessment, and subjects quality of life scores over 6
      months in adult females treated with Next Science™ acne cream 2x or Next Science™ acne cream
      1x in a double blind manner.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 6-month, single-site, double-blind, controlled study in 20 female subjects with
      mild to moderate facial acne. Subjects will be randomized 1:1 to apply either topical Next
      Science™ acne cream 2x or Next Science™ acne cream 1x daily. Subjects will be evaluated for
      clinical acne and quality of life outcomes at baseline, 6, 12, 18 and 24 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Decision from the Sponsor
  </why_stopped>
  <start_date type="Actual">March 27, 2017</start_date>
  <completion_date type="Actual">August 14, 2017</completion_date>
  <primary_completion_date type="Actual">August 14, 2017</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in Lesion Count</measure>
    <time_frame>Baseline versus 6 months</time_frame>
    <description>Inflammatory acne lesions with both study acne cream products after 6 months of treatment compared to baseline. This will be measured as the mean percent change from baseline to week 24 in the inflammatory lesion count.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inflammatory Lesion count over time</measure>
    <time_frame>weeks 6, 12, 18, and 24</time_frame>
    <description>to assess the mean percent change from baseline to weeks 6, 12, 18, and 24 inflammatory lesion counts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-inflammatory acne lesion over time</measure>
    <time_frame>weeks 6, 12, 18, and 24</time_frame>
    <description>to assess the mean percent change from baseline to weeks 6, 12, 18, and 24 in non-inflammatory lesion counts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator Global Assessment over time</measure>
    <time_frame>weeks 6, 12, 18, and 24</time_frame>
    <description>to assess the mean percent change from baseline to weeks 6, 12, 18, and 24 in IGA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Areas over time</measure>
    <time_frame>weeks 6, 12, 18, and 24</time_frame>
    <description>to assess the mean percent change from baseline to weeks 6, 12, 18, and 24 in treatment areas (erythema, dryness, stinging or burning, erosion, edema, pain and itching)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life over time</measure>
    <time_frame>weeks 6, 12, 18, and 24</time_frame>
    <description>The Acne-QoL questionnaire containing 19 questions organized into four domains which address the impact of facial acne on health-related quality of life will be administered. These are Self Perception, Role-social, Role-emotional and Acne Symptoms. Results will assess the mean percent change from baseline to weeks 6, 12, 18, and 24 in QoL.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Acne cream 1x</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Twice-daily facial applications of the 1X product (avoiding contact with eyes and all mucous membranes) to the entire face for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acne cream 2x</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Twice-daily facial applications of the 2X product (avoiding contact with eyes and all mucous membranes) to the entire face for 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acne cream 2X</intervention_name>
    <description>Twice daily application of facial acne cream 2X after facial cleansing</description>
    <arm_group_label>Acne cream 2x</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acne cream 1X</intervention_name>
    <description>Twice daily application of facial acne cream 1X after facial cleansing</description>
    <arm_group_label>Acne cream 1x</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female ages 18 and above

          2. Has 20 or more inflammatory lesions on the face (papules and pustules) as determined
             by qualified examiner at Start of Treatment.

          3. In the area to be treated, has no significant facial dermatological conditions other
             than acne (as determined by the investigator) that would interfere with any study
             treatment or procedure

          4. Is willing and able to discontinue use of all baseline acne treatments for the
             duration of their trial participation

          5. Agrees to refrain from professional facial treatments during their trial
             participation.

          6. Agrees to avoid tanning booth use and minimize sun exposure during their trial
             participation.

          7. Is willing and able to follow instructions and procedures including attending
             scheduled study visits, which will require adequate transportation to the study site

          8. Is able to read, understand and sign the informed consent document and communicate
             with study staff and investigator.

        Exclusion Criteria:

          1. Has more than 2 nodules/cystic acne lesions on the face

          2. Has a history of significant reactions to topical acne treatments, or a known allergy
             or hypersensitivity to any listed ingredients

          3. Has any history of skin malignancy

          4. Has used any systemic medications (including antibiotics, estrogens, retinoids)
             primarily for treatment of acne in the 21 days prior to randomization.

          5. Has used estrogens primarily as treatment for acne in the 21 days prior to
             randomization (estrogens prescribed for other reasons will be allowed if stable for at
             least 30 days prior to randomization).

          6. Has had any professional facial treatments in the 14 days prior to randomization.

          7. Has received any investigational treatment in the 30 days prior to randomization.

          8. Have any significant medical problems or other issues that would, in the
             investigator's judgment, affect their suitability for participation in this trial.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matt Myntti, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Next Science</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Skin Laser &amp; Surgery Specialists of NY &amp; NJ</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2017</study_first_submitted>
  <study_first_submitted_qc>April 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2017</study_first_posted>
  <last_update_submitted>August 28, 2017</last_update_submitted>
  <last_update_submitted_qc>August 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

